Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Revenue projections:

Revenue projections for RMD
Revenue projections for RMD

RMD's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 3.060000
forwardPE 16.897593
debtToEquity 13.411000
earningsGrowth 0.145000
revenueGrowth 0.110000
grossMargins 0.614740
operatingMargins 0.351630
trailingEps 10.370000
forwardEps 12.133090

A current ratio of 3.06 for RMD implies that the company has ample liquidity to meet its short-term debts. RMD's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
RMD's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
ResMed Inc.'s low Debt-to-Equity ratio indicates the company is not over-leveraged. By limiting its dependence on debt, ResMed Inc. reduces its financial risk and demonstrates a strong capital structure, making it a more stable investment option for those wary of excessive borrowing.
Positive earnings and revenue growth for RMD suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
With positive gross and operating margins, RMD demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
RMD's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in RMD's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for RMD
Price projections for RMD

The current valuation of RMD, compared to projections, does not highlight any specific risks or opportunities. This stable scenario may lead investors to adopt a wait-and-see approach as they monitor future developments for potential shifts in the market.

Insider Transactions:

Insider Transactions for RMD
Insider Transactions for RMD


42 sales transactions of RMD were conducted, with market price at 250.1702390398298.During the period under consideration, no sell transactions took place.RMD's current price levels are experiencing more buying activity than selling, which may point to a favorable outlook. This trend suggests investor confidence in the stock's future, potentially indicating expectations of continued growth.

Recommendation changes over time:

Recommendations trend for RMD
Recommendations trend for RMD


RMD has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view RMD as a stable option to park their money and potentially benefit from the company's continued growth and profitability.